BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions, Inc. has entered into a multi-year supply agreement with Qkine Limited to distribute specific cytokine and growth factor products for the cell and gene therapy (CGT) market. This partnership grants BioLife exclusive global distribution rights for certain Qkine products and non-exclusive rights for others in the CGT sector. The collaboration aims to integrate Qkine’s products with BioLife’s CellSeal® Connect vial system and enhance BioLife's offerings in the rapidly growing cytokines market.
BioLife Solutions, Inc. (BLFS): Analyst Consensus Signals 45.95% Potential Upside
BioLife Solutions, Inc. (BLFS) is attracting significant investor attention within the healthcare sector, particularly in cell and gene therapy. Despite negative earnings, the company shows strong revenue growth and innovative product offerings, leading analysts to project a 45.95% potential upside with an average target price of $32.44. Technical indicators are mixed, but overwhelmingly positive analyst sentiment suggests confidence in its future performance.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its 2025 fourth quarter and full year financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET that day to discuss the financial results and provide a business update. A webcast replay will be available for 90 days following the call.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET on that day to provide an overview of the financial results and a general business update. BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy market.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its 2025 fourth quarter and full year financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET (1:30 PM PT) on that day to discuss the results and provide a business update. Investors and interested parties can access the webcast via the company's investor relations website.
How BioLife’s Exclusive Qkine Cytokine Deal Could Rewire the BLFS Cell and Gene Therapy Story
BioLife Solutions recently announced an exclusive multi-year distribution agreement with Qkine Limited for cytokine and growth factor products used in cell and gene therapy manufacturing. This deal expands BioLife's reach into the growing cytokines market, estimated to double to US$1 billion by 2030, and aims to integrate Qkine's products into BioLife’s CellSeal® Connect vial system. The partnership is expected to strengthen BioLife’s investment narrative by adding a new revenue stream and deepening its role in CGT process optimization.
BioLife Solutions (BLFS) Receives a Buy from Lake Street
Lake Street analyst Thomas Flaten maintained a Buy rating on BioLife Solutions (BLFS) with a $33.00 price target, aligning with a recent Buy rating from Northland Securities. This positive outlook comes despite a Hold rating from TipRanks – Google and negative corporate insider sentiment with increased selling activity in Q4 2025. The company recently reported Q3 revenue of $28.07 million and a net profit of $621 thousand, compared to a revenue of $30.57 million and a GAAP net loss of $1.7 million in the prior year.
BioLife Solutions (NASDAQ:BLFS) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?
BioLife Solutions (NASDAQ:BLFS) stock experienced a technical breach, falling below its 200-day moving average of $25.11 to trade as low as $21.45. Analysts have a "Moderate Buy" consensus rating with an average price target of $32.00, despite recent insider selling totaling approximately $1.23 million. Institutional investors hold a significant 93.24% stake in the company, which has a market capitalization of $1.04 billion and a negative P/E ratio.
Biolife Solutions Signs Multi-Year Supply Agreement With Qkine Limited
Biolife Solutions (BLFS) has announced a multi-year supply agreement with Qkine Limited. This agreement is expected to strengthen Biolife's market position, particularly within the US stocks industrial sector. The news is brief and highlights a strategic business development for the company.
BioLife Solutions, Inc. Signs Multi-Year Supply Agreement with Qkine Limited to Expand Its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions, Inc. has signed a multi-year supply agreement with Qkine Limited, giving BioLife exclusive worldwide distribution rights for certain Qkine cytokine and growth factor products used in cell and gene therapy manufacturing. This partnership is expected to expand BioLife's product portfolio into the rapidly growing global cytokines market, which is projected to reach $1 billion by 2030. The companies also plan to collaborate on integrating Qkine's products with BioLife's CellSeal® Connect vial system for closed-system CGT workflows.
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions, Inc. has signed a multi-year supply agreement with Qkine Limited, granting BioLife exclusive worldwide distribution rights to certain Qkine cytokine and growth factor products for the cell and gene therapy (CGT) market. This partnership aims to expand BioLife's product portfolio with complementary offerings and includes a collaboration to integrate Qkine's products with BioLife's CellSeal® Connect vial system for closed system CGT workflows. The agreement positions BioLife to capitalize on the rapidly growing cytokines market, estimated to reach $1 billion by 2030.
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions has entered into a multi-year supply agreement with Qkine Limited, granting BioLife exclusive worldwide distribution rights for specific Qkine cytokine and growth factor products within the cell and gene therapy (CGT) market. This partnership aims to expand BioLife's product portfolio with highly complementary offerings and includes a collaboration to integrate Qkine products with BioLife's CellSeal® Connect vial system for improved CGT workflows. The agreement positions BioLife to capitalize on the rapidly growing global cytokines market, projected to reach $1 billion by 2030, by providing essential tools for next-generation cell and gene therapies.
H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock
H.C. Wainwright has reiterated its Buy rating on BioLife (BLFS) stock. The analyst firm believes BioLife holds a strong market position and that its current valuation offers an attractive entry point for investors. This continued positive outlook suggests potential for growth in the company's stock value.
BioLife Solutions Inc (BLFS) Stock Price Down 4.32% on Jan 28
BioLife Solutions Inc (BLFS) shares dropped 4.32% on January 28, trading at $23.90 after an intraday low of $23.81. This places the stock 19.31% below its 52-week high, with analysts setting an average price target of $32.22, indicating a potential 34.82% upside. GuruFocus estimates a fair value (GF Value) of $28.48, suggesting a 19.16% upside from its current price.
BioLife Solutions, Inc. (BLFS): Investor Outlook With A 32.86% Potential Upside
BioLife Solutions, Inc. (BLFS) is attracting investor attention in the healthcare sector due to its crucial role in the cell and gene therapy (CGT) industry. Despite negative EPS and ROE, the company shows robust revenue growth powered by innovative biopreservation products. Analysts are optimistic, with a consensus predicting a 32.86% potential upside, making BLFS a compelling stock for growth-oriented investors amidst market volatility.
Stronger Q4 Revenue and Leadership Change Might Change The Case For Investing In BioLife Solutions (BLFS)
BioLife Solutions (BLFS) recently reported unaudited Q4 2025 revenue that exceeded guidance, showing a 20% increase. This strong financial performance, combined with the successful divestiture of the evo product line and an upcoming leadership transition, positions BioLife as a more focused cell processing company. Investors are now evaluating how these changes might influence the company's profitability, long-term growth, and existing investment narrative, especially considering customer concentration risks.
BioLife Solutions reports 20% revenue growth in Q4 2025 By Investing.com
BioLife Solutions (NASDAQ:BLFS) announced preliminary unaudited Q4 2025 revenue from continuing operations of $24.8 million, marking a 20% increase year-over-year. For the full year 2025, the company's revenue from continuing operations reached $96.2 million, exceeding guidance. Following recent divestitures, BioLife Solutions is now positioned as a pure-play cell processing company and expects continued revenue growth and adjusted EBITDA margin expansion in 2026.
Summit Creek Advisors LLC Makes New Investment in BioLife Solutions, Inc. $BLFS
Summit Creek Advisors LLC has made a new investment in BioLife Solutions, Inc. by acquiring 192,261 shares valued at approximately $4.9 million, increasing institutional ownership to 93.24%. Despite this, BioLife Solutions has seen significant insider selling, with the CFO and CEO disposing of shares totaling over $1.8 million in recent months. Analysts currently maintain a consensus "Hold" rating for BLFS, with an average price target near $32, while the stock trades around $24.86.
BioLife Solutions reports 20% revenue growth in Q4 2025
BioLife Solutions (NASDAQ:BLFS) reported strong preliminary unaudited fourth-quarter revenue of $24.8 million, a 20% increase year-over-year, and full-year 2025 revenue of $96.2 million, surpassing guidance. The company, which specializes in cell processing tools, has completed several divestitures to focus on high-value, recurring revenue franchises. Despite its current stock appearing overvalued according to InvestingPro data, BioLife Solutions maintains a healthy financial position with low debt and positive analyst ratings.
Biolife Solutions Announces Preliminary Fourth Quarter And Full Year 2025 Unaudited Revenue From Continuing Operations
Biolife Solutions (BLFS) has announced its preliminary unaudited revenue from continuing operations for the fourth quarter and full year 2025. This news item provides a headline regarding their financial performance but does not include further details.
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
BioLife Solutions (Nasdaq: BLFS) announced preliminary unaudited revenue from continuing operations for Q4 2025 was $24.8 million, a 20% increase from the prior year, and full-year 2025 revenue was $96.2 million, exceeding guidance. This growth follows the divestiture of its evo product line, positioning BioLife as a pure-play cell processing company. The company anticipates continued revenue growth and adjusted EBITDA margin expansion in 2026.
BioLife Solutions reports 20% revenue growth in Q4 2025 By Investing.com
BioLife Solutions (NASDAQ:BLFS) announced a 20% increase in Q4 2025 revenue from continuing operations, totaling $24.8 million, and full-year 2025 revenue of $96.2 million, exceeding guidance. The company, a supplier for the cell and gene therapy market, attributed this growth to its strategic divestitures to become a pure-play cell processing company. Despite the positive revenue figures, InvestingPro data suggests the stock is currently overvalued compared to its Fair Value, while H.C. Wainwright reiterated a Buy rating with a $32.00 price target.
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
BioLife Solutions announced preliminary unaudited revenue from continuing operations for Q4 and full year 2025. Fourth-quarter revenue increased by 20% to $24.8 million, while full-year revenue reached $96.2 million, exceeding guidance. This strong performance follows the divestiture of its evo product line, positioning BioLife Solutions as a pure-play cell processing company focused on recurring revenue.
Biolife Solutions CMO Berard sells $8.8k in shares By Investing.com
Biolife Solutions' Chief Marketing Officer, Todd Berard, sold 344 shares for $8,802 on January 6, 2026, under a pre-arranged 10b5-1 trading plan to cover tax obligations. The company recently reported strong Q3 2025 earnings, exceeding revenue and EPS forecasts, and opened a new biopreservation facility. H.C. Wainwright reiterated a Buy rating with a $32.00 price target.
BioLife Solutions announces planned retirement of key executive
BioLife Solutions (BLFS) announced that its Chief Quality and Operations Officer, Karen Foster, will retire on March 31, 2026. The company stated that her retirement is not due to any disagreements and signifies a planned, smooth leadership transition. TipRanks' AI Analyst, Spark, rates BLFS as Neutral, citing strong revenue growth but also declining revenues and profitability, bearish technical indicators, and overvaluation.
Aby J. Mathew, Biolife Solutions evp, sells $10k in shares
Biolife Solutions Executive Vice President and Chief Scientific Officer, Aby J. Mathew, sold 405 shares of common stock for a total of $10,363 to cover tax obligations. The sale was executed under a Rule 10b5-1 trading plan. This insider transaction follows BioLife Solutions' strong Q3 2025 earnings and the opening of the Aby J. Mathew Center for Biopreservation Excellence.
Insider Selling: BioLife Solutions (NASDAQ:BLFS) CFO Sells 990 Shares of Stock
BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman recently sold 990 shares of the company's stock for approximately $25,334, reducing his holdings by 0.65%. This transaction is part of a series of sales by Wichterman, including a significant sale of 30,000 shares in December. The company's stock experienced a 1.8% drop, and institutional investors hold a substantial portion of the shares, while analysts have a mixed "Hold" rating with an average target price of $32.00.
Aby J. Mathew, Biolife Solutions evp, sells $10k in shares
Aby J. Mathew, Executive Vice President and Chief Scientific Officer at Biolife Solutions (NASDAQ:BLFS), recently sold 405 shares of common stock for $10,363 to cover tax obligations. This sale was part of a pre-arranged trading plan. BioLife Solutions also reported strong Q3 2025 earnings, exceeding analyst expectations, and opened a new biopreservation facility named after Mathew.
Troy Wichterman, Biolife Solutions CFO, sells $25k in shares
Biolife Solutions CFO Troy Wichterman sold 990 shares of common stock for $25,334 on January 6, 2026, under a pre-arranged 10b5-1 trading plan to cover tax obligations. This sale comes after the company reported strong Q3 2025 earnings, exceeding revenue and EPS forecasts. H.C. Wainwright maintained a "Buy" rating on BLFS with a $32.00 price target.
Foster, chief quality at BioLife, sells $8572 in shares
Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions Inc, sold 335 shares of the company's common stock for $8572. This transaction was part of a pre-arranged trading plan to cover tax obligations. Concurrently, BioLife Solutions reported strong Q3 2025 earnings, opened a new biopreservation facility, and received a reiterated Buy rating from H.C. Wainwright.
Troy Wichterman, Biolife Solutions CFO, sells $25k in shares
Biolife Solutions CFO Troy Wichterman sold 990 shares of common stock for approximately $25,334 to cover tax obligations. This sale was part of a pre-arranged trading plan. Separately, BioLife Solutions reported strong Q3 2025 earnings, exceeding revenue and EPS forecasts, and H.C. Wainwright reiterated a Buy rating on the company.
Aby J. Mathew, Biolife Solutions evp, sells $10k in shares
Aby J. Mathew, EVP and Chief Scientific Officer at Biolife Solutions INC, sold 405 shares totaling $10,363 to cover tax obligations. This sale was part of a pre-planned trading strategy. The company recently reported strong Q3 2025 earnings, surpassing analyst expectations, and inaugurated the Aby J. Mathew Center for Biopreservation Excellence.
Biolife Solutions CMO Berard sells $8.8k in shares
Todd Berard, CMO of Biolife Solutions Inc (NASDAQ:BLFS), sold 344 shares for $8,802 on January 6, 2026, due to a pre-arranged tax obligation trading plan. This transaction follows recent positive Q3 2025 earnings for BioLife Solutions and the opening of a new biopreservation facility, with H.C. Wainwright reiterating a Buy rating.
Biolife Solutions CMO Berard sells $8.8k in shares
Todd Berard, the Chief Marketing Officer of BioLife Solutions Inc (NASDAQ:BLFS), sold 344 shares of company stock worth $8,802 on January 6, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan to cover tax obligations. The article also highlights BioLife Solutions' strong Q3 2025 earnings and the opening of a new biopreservation center, with H.C. Wainwright reiterating a Buy rating.
BioLife Solutions, Inc. (BLFS) Stock Analysis: 28% Upside Potential and Strong Revenue Growth
BioLife Solutions, Inc. (BLFS) is a key player in the cell and gene therapy (CGT) industry, showing significant revenue growth despite negative EPS. Analysts are bullish on the stock, with an average target price suggesting a 28% upside. The company's innovative biopreservation and shipping solutions, along with positive technical indicators, position it as an attractive option for growth-oriented investors in the high-growth healthcare sector.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Rating of "Moderate Buy" by Brokerages
BioLife Solutions, Inc. (NASDAQ:BLFS) has received an average rating of "Moderate Buy" from six brokerages, with four analysts assigning a "buy" rating, one a "hold," and one a "sell." The average one-year price target is set at $31.00. Notable insider selling includes CEO Greef Roderick De, who sold 31,165 shares, and other insiders who collectively sold 937,664 shares valued at $26.31 million in the last 90 days.
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 43% Undervaluation?
BioLife Solutions, Inc. (NASDAQ:BLFS) appears undervalued by 43% according to a Discounted Cash Flow (DCF) model, with a projected fair value of US$42.24 against a current share price of US$24.18. Analysts have a price target of US$32.10, which is below the calculated fair value. The analysis uses a 2-stage growth model and highlights the importance of the discount rate and future cash flow estimates for valuation.
BioLife Solutions (NASDAQ:BLFS) investor five-year losses grow to 39% as the stock sheds US$59m this past week
BioLife Solutions (NASDAQ:BLFS) shareholders have experienced a 39% loss over the last five years, with the stock shedding US$59 million this past week. The company, which is not yet profitable, has shown a modest revenue growth of 1.4% annually over the same period. This raises concerns about its sustainability and ability to achieve profitability without faster revenue expansion.
BioLife Solutions (NASDAQ:BLFS investor five-year losses grow to 39% as the stock sheds US$59m this past week
BioLife Solutions (NASDAQ:BLFS) shareholders have experienced a 39% loss over the past five years, with the stock recently shedding US$59 million in value. The company, which is not yet profitable, has shown a modest revenue growth of 1.4% annually over the same period. While recent investor losses are less severe than the five-year trend, the company needs to improve profitability or revenue growth to regain investor confidence.
BioLife Solutions (NASDAQ:BLFS investor five-year losses grow to 39% as the stock sheds US$59m this past week
BioLife Solutions (NASDAQ:BLFS) shareholders have experienced a 39% loss over the past five years, with an additional US$59 million market cap reduction last week. The company, which is not yet profitable, has shown a modest revenue growth of 1.4% annually over the same period. This limited growth and unprofitability contribute to the stock's poor performance, prompting investors to seek future profitability.
BioLife Solutions stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright has reiterated its Buy rating on BioLife Solutions (NASDAQ:BLFS), setting a price target of $32.00, which suggests approximately 29% upside from the current price. The firm adjusted its financial statements for 2024 and 2025 to exclude revenue from its divested evo cold chain logistics subsidiary, aligning with management's FY2025 revenue guidance of $95.0-96.0 million. This re-affirmation follows BioLife Solutions' strong Q3 2025 earnings and the opening of the Aby J. Mathew Center for Biopreservation Excellence.
BioLife Solutions stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright has reiterated its Buy rating on BioLife Solutions (NASDAQ:BLFS) with a price target of $32.00, aligning with the broader analyst consensus. The firm adjusted its financials to exclude revenue from a divested subsidiary and projects FY2025 revenue of $95.8 million, with FY2026 revenue projected at $112.6 million. This follows recent positive earnings results and the opening of a new biopreservation excellence center.
Insider Sell: Amy Duross Sells 2,000 Shares of BioLife Solutions Inc (BLFS)
Amy Duross, a Director at BioLife Solutions Inc (BLFS), sold 2,000 shares of the company on December 15, 2025, reducing her holdings to 18,687 shares. This transaction follows 95 insider sells and no buys over the past year for BLFS. The stock was trading at $24.6, indicating it is "Fairly Valued" based on its GF Value.
BioLife Solutions' CFO Sells 30,000 Shares
BioLife Solutions' (NASDAQ:BLFS) CFO, Troy Wichterman, sold 30,000 shares of the company stock on December 4th, for approximately $771,600. This insider sale occurred amid a modest downtrend in the share price of the bioproduction tools provider for cell and gene therapy. The transaction value was based on a weighted average sale price of $25.72 according to the SEC Form 4 filing.
BioLife Solutions (BLFS) CFO Wichterman sells $771,600 in stock By Investing.com
BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman sold 30,000 shares of company stock for $771,600 in early December 2025. This transaction, occurring at an average price of $25.72 per share, leaves Wichterman with 152,769 shares. The sale comes amidst positive company news, including strong Q3 2025 earnings and the opening of a new biopreservation facility.
Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
BioLife Solutions, Inc. (NASDAQ:BLFS) currently has a high price-to-sales (P/S) ratio of 12.2x, significantly above the industry average, which suggests it might be overvalued. However, this high P/S ratio is likely justified by its strong recent revenue growth of 88% and an anticipated 18% annual revenue increase over the next three years, outperforming the industry forecast of 6.6%. Investors appear confident in the company's future prospects, leading to the elevated P/S ratio.
BioLife Solutions (BLFS) CFO Wichterman sells $771,600 in stock By Investing.com
BioLife Solutions Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 30,000 shares of company stock for $771,600 on December 4, 2025. Following the transaction, Wichterman directly owns 152,769 shares. This sale comes amidst positive company developments, including Q3 2025 revenue exceeding forecasts, better-than-anticipated EPS, and the opening of a new biopreservation facility.
BioLife Solutions (BLFS) CFO Wichterman sells $771,600 in stock
BioLife Solutions Inc (NASDAQ:BLFS) CFO Troy Wichterman sold 30,000 shares of common stock for $771,600 on December 4, 2025, according to an SEC filing. This transaction occurred at a weighted average price of $25.72 per share, with prices ranging from $25.53 to $25.84, leaving him with 152,769 directly owned shares. The sale follows a strong Q3 2025 earnings report, exceeding revenue and EPS forecasts, and the recent opening of the Aby J. Mathew Center for Biopreservation Excellence.
BioLife Solutions CFO Sells 30,000 Shares
Troy Wichterman, CFO and 10% owner of BioLife Solutions (BLFS), sold 30,000 shares of common stock for $771,600 on December 4, 2025. The shares were sold at a weighted average price of $25.72 each. After this transaction, Wichterman directly owns 152,769 shares of the company.
Opening of New Biopreservation Center Might Change the Case for Investing in BioLife Solutions (BLFS)
BioLife Solutions (BLFS) recently opened the Aby J. Mathew Center for Biopreservation Excellence to advance cell and tissue preservation technologies, integrating proprietary ice recrystallization inhibitor technology. This move aims to enhance cryopreservation methods and foster collaboration within the cell and gene therapy sector, potentially reshaping the company's investment narrative and growth prospects. While the immediate business outlook may not change significantly, the center aligns with BioLife’s focus on capturing growing demand and accelerating next-generation product development, supporting their 2025 revenue guidance of US$95.0 million to US$96.0 million.
